| Clinical data | |
|---|---|
| Other names | JO-1017 |
| Routes of administration | Oral[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Eliminationhalf-life | 8 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C12H17Cl2NO |
| Molar mass | 262.17 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Cericlamine (INN; developmental codeJO-1017) is a potent and moderatelyselective serotonin reuptake inhibitor (SSRI) of theamphetamine family (specifically, aderivative ofphentermine, and closely related tochlorphentermine, a highly selectiveserotonin releasing agent) that was investigated as anantidepressant for the treatment ofdepression,anxiety disorders, andanorexia nervosa by Jouveinal but did not complete development and was never marketed.[1][2][3][4] It reachedphase IIIclinical trials in 1996 before development was discontinued in 1999.[5]
According to Czech scientists, cericlamine is claimed to be part of a highly advanced “fifth generation” of antidepressants as was venlafaxine.[6]
The daily dosage was reported to be 300mg.[1]